Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CagriSema
Fierce Pharma
Novo struggles to appease restless investors with new strategy
CEO Mike Doustdar acknowledged that the company’s leadership “have to convince” investors that “there is a bright future for Novo.”
James Waldron
,
Fraiser Kansteiner
Sep 21, 2026 10:50am
Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
Aug 7, 2026 9:08am
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Aug 7, 2026 8:42am
Novo CEO accepts ‘couple of setbacks,’ hunts for bolt-on deals
Aug 5, 2026 8:00am
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
Jul 29, 2026 10:30am
Fierce Pharma
Obesity meds, China drive $2T in projected 2032 drug sales: report
Jun 23, 2026 9:00am
